CYTOMX THERAPEUTICS INC's ticker is CTMX and the CUSIP is 23284F105. A total of 125 filers reported holding CYTOMX THERAPEUTICS INC in Q3 2018. The put-call ratio across all filers is 0.67 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $327,638,000 | -20.2% | 64,369 | -0.7% | 0.00% | – |
| Q2 2021 | $410,495,000 | +79.4% | 64,849 | +119.1% | 0.00% | – |
| Q1 2021 | $228,769,000 | -29.3% | 29,595 | -40.1% | 0.00% | – |
| Q4 2020 | $323,381,000 | -1.5% | 49,371 | 0.0% | 0.00% | – |
| Q3 2020 | $328,318,000 | +27.4% | 49,371 | +59.6% | 0.00% | – |
| Q2 2020 | $257,656,000 | +22.5% | 30,931 | +12.8% | 0.00% | – |
| Q1 2020 | $210,296,000 | -26.8% | 27,418 | -20.7% | 0.00% | – |
| Q4 2019 | $287,385,000 | +5.1% | 34,583 | -6.7% | 0.00% | – |
| Q3 2019 | $273,459,000 | -14.7% | 37,054 | +29.7% | 0.00% | – |
| Q2 2019 | $320,489,000 | +21.2% | 28,564 | +16.2% | 0.00% | – |
| Q1 2019 | $264,343,000 | +34.7% | 24,590 | +89.2% | 0.00% | – |
| Q4 2018 | $196,300,000 | -18.4% | 13,000 | 0.0% | 0.00% | – |
| Q3 2018 | $240,500,000 | -13.1% | 13,000 | +7.4% | 0.00% | – |
| Q2 2018 | $276,606,000 | – | 12,100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 6,450,000 | $8,320,500 | 1.17% |
| BVF INC/IL | 6,595,801 | $8,508,583 | 0.23% |
| Bronte Capital Management Pty Ltd. | 925,245 | $1,193,566 | 0.12% |
| Formidable Asset Management, LLC | 318,111 | $410,363 | 0.09% |
| Congress Park Capital LLC | 112,450 | $145,061 | 0.08% |
| Forefront Analytics, LLC | 49,421 | $63,754 | 0.04% |
| Ground Swell Capital, LLC | 10,966 | $14,146 | 0.02% |
| Clearline Capital LP | 196,583 | $253,592 | 0.02% |
| CORNERCAP INVESTMENT COUNSEL INC | 81,352 | $104,944 | 0.02% |
| ACADIAN ASSET MANAGEMENT LLC | 2,646,190 | $3,412 | 0.01% |